Arcus Biosciences, Inc. (RCUS) is a publicly traded Healthcare sector company. As of May 21, 2026, RCUS trades at $23.82 with a market cap of $2.94B and a P/E ratio of -7.37. RCUS moved +4.48% today. Year to date, RCUS is +9.05%; over the trailing twelve months it is +167.64%. Its 52-week range spans $6.50 to $28.72. Analyst consensus is strong buy with an average price target of $35.89. Rallies surfaces RCUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for RCUS combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $23.82 |
| Market Cap | $2.94B |
| P/E Ratio | -7.37 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.72 |
| 52-Week Low | $6.50 |
| Volume | 113 |
| Avg Volume | 0 |
| Revenue (TTM) | $236.00M |
| Net Income | $-369.00M |
| Gross Margin | 0.00% |
10 analysts cover RCUS: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.89.